NLK is a novel therapeutic target for PTEN deficient tumour cells - PubMed (original) (raw)
NLK is a novel therapeutic target for PTEN deficient tumour cells
Ana M Mendes-Pereira et al. PLoS One. 2012.
Abstract
PTEN (Phosphatase and tensin homolog) is a tumour suppressor gene commonly defective in human cancer, and is thus a potentially important therapeutic target. Targeting tumour suppressor loss-of-function is possible by exploiting the genetic concept of synthetic lethality (SL). By combining the use of isogenic models of PTEN deficiency with high-throughput RNA interference (RNAi) screening, we have identified Nemo-Like Kinase (NLK) inhibition as being synthetically lethal with PTEN deficiency. This SL is likely mediated by the transcription factor FOXO1 (Forkhead box O1), an NLK substrate, as the selectivity of NLK gene silencing for PTEN deficient cells can be reversed by FOXO1 knockdown. In addition, we provide evidence that PTEN defective cells targeted by NLK gene depletion undergo senescence, suggesting that NLK function is critical for the continued proliferation of PTEN deficient cells. Taken together, these data provide new insight into the potential of targeting of NLK to treat a range of tumourigenic conditions characterised by PTEN deficiency.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Figure 1. PTEN synthetic lethality screening.
(A) High-throughput screen (HTS) schematic. PTEN proficient and deficient HCT116 cells (Horizon Discovery) were siRNA screened as described in the Methods. Example heatmaps from luminescence measurements in 96 well plates are shown. For screening, a siGENOME SMARTPool library (Dharmacon) targeting 779 kinases and kinase-related genes was used. (B) Results from data analysis of combined triplicate screens, represented as a scatter plot of Normalised Percent Inhibition (NPI) values from HCT116 PTEN−/− and HCT116 PTEN+/+ screens. Blue dots corresponded to siPLK effects and red dots corresponded to siCON negative control effects. NPI values below the trend line shown were considered as candidate synthetic lethalities. (C) Validation of PTEN synthetic lethal hits from the HTS using multiple siRNAs for each gene. Cells were transfected with siRNA as per the HTS and surviving fractions calculated from CellTiterGlo luminescence measurements five days later. Surviving fraction data from HCT116 PTEN−/− and HCT116 PTEN+/+ cells transfected with each siRNA are shown. (D) Western blot showing silencing effects of each siRNA.
Figure 2. Validation of the PTEN/NLK synthetic lethality.
(A) Validation of PTEN synthetic lethal hits in additional isogenic models. Isogenic HCT116, DLD1 and HEC1A PTEN proficient and deficient models were transfected with siRNA as in Figure 1 and surviving fractions calculated five days later. Surviving fraction data from HCT116, HEC1A and DLD1 models is shown. * p value<0.05 Student's t test (B) Western blot showing expression of each candidate gene in three PTEN isogenic models. (C) Cell inhibitory effect of siRNA targeting NLK or PLK4 in a panel of 24 human tumour cell lines (11 PTEN proficient models and 13 PTEN deficient models – see Table 1). (D) Box plots illustrating surviving fraction data for PTEN proficient and deficient groups shown in (C). _p_-values were calculated with Student's _t_-test.
Figure 3. PTEN/NLK synthetic lethality is abrogated by FOXO1 silencing.
(A) Survival analysis of HCT116 cells transfected with NLK and/or FOXO1 siRNA. HCT116 PTEN−/− and HCT116 PTEN+/+ cells were transfected with siRNA targeting NLK and FOXO1 as shown and surviving fractions determined after five days. The p value (*) was calculated using Student's t test. (B) Nuclear localisation of FOXO1 is enhanced in PTEN deficient cells upon NLK silencing. HCT116 isogenic cells were co-transfected with GFP-tagged FOXO1 cDNA in addition to control (non targeting) siRNA (siCON) or NLK siRNA. Two days later cells were fixed and stained with DAPI. Green signal represents GFP-FOXO1 and blue signal represents nuclear DAPI (nuclear) staining. Arrows indicate cells with nuclear localisation of FOXO1. (C) Senescence is increased by NLK siRNA in PTEN deficient cells. Bar chart of relative relative senescence levels caused by NLK silencing are shown. HCT116-derived PTEN isogenic cell lines were reversed transfected with a pool of two validated siRNAs against NLK, as well as siCON pool#2 (Dharmacon) as non-targeting control, using RNAiMAX (Invitrogen). Seven days after transfection cells were fixed and incubated overnight at 37°C in a solution containing X-gal. (D) Representative images for β-Galactosidase staining of PTEN deficient cells. Blue staining indicates β-Galactosidase.
Similar articles
- Inhibition of FOXO1/3 promotes vascular calcification.
Deng L, Huang L, Sun Y, Heath JM, Wu H, Chen Y. Deng L, et al. Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):175-83. doi: 10.1161/ATVBAHA.114.304786. Epub 2014 Nov 6. Arterioscler Thromb Vasc Biol. 2015. PMID: 25378413 Free PMC article. - FOXO1/3 and PTEN Depletion in Granulosa Cells Promotes Ovarian Granulosa Cell Tumor Development.
Liu Z, Ren YA, Pangas SA, Adams J, Zhou W, Castrillon DH, Wilhelm D, Richards JS. Liu Z, et al. Mol Endocrinol. 2015 Jul;29(7):1006-24. doi: 10.1210/me.2015-1103. Epub 2015 Jun 10. Mol Endocrinol. 2015. PMID: 26061565 Free PMC article. - PTEN regulates adipose progenitor cell growth, differentiation, and replicative aging.
Kirstein AS, Kehr S, Nebe M, Hanschkow M, Barth LAG, Lorenz J, Penke M, Breitfeld J, Le Duc D, Landgraf K, Körner A, Kovacs P, Stadler PF, Kiess W, Garten A. Kirstein AS, et al. J Biol Chem. 2021 Aug;297(2):100968. doi: 10.1016/j.jbc.2021.100968. Epub 2021 Jul 14. J Biol Chem. 2021. PMID: 34273354 Free PMC article. - The INPP4B paradox: Like PTEN, but different.
Hamila SA, Ooms LM, Rodgers SJ, Mitchell CA. Hamila SA, et al. Adv Biol Regul. 2021 Dec;82:100817. doi: 10.1016/j.jbior.2021.100817. Epub 2021 Jun 16. Adv Biol Regul. 2021. PMID: 34216856 Review. - PI(3)king apart PTEN's role in cancer.
Zhang S, Yu D. Zhang S, et al. Clin Cancer Res. 2010 Sep 1;16(17):4325-30. doi: 10.1158/1078-0432.CCR-09-2990. Epub 2010 Jul 8. Clin Cancer Res. 2010. PMID: 20622047 Review.
Cited by
- The Future of Targeted Therapy for Leiomyosarcoma.
Denu RA, Dann AM, Keung EZ, Nakazawa MS, Nassif Haddad EF. Denu RA, et al. Cancers (Basel). 2024 Feb 26;16(5):938. doi: 10.3390/cancers16050938. Cancers (Basel). 2024. PMID: 38473300 Free PMC article. Review. - Synthetic lethal approaches to target cancers with loss of PTEN function.
Ertay A, Ewing RM, Wang Y. Ertay A, et al. Genes Dis. 2023 Nov;10(6):2511-2527. doi: 10.1016/j.gendis.2022.12.015. Genes Dis. 2023. PMID: 37533462 Free PMC article. - Strategies to Enhance Logic Modeling-Based Cell Line-Specific Drug Synergy Prediction.
Niederdorfer B, Touré V, Vazquez M, Thommesen L, Kuiper M, Lægreid A, Flobak Å. Niederdorfer B, et al. Front Physiol. 2020 Jul 28;11:862. doi: 10.3389/fphys.2020.00862. eCollection 2020. Front Physiol. 2020. PMID: 32848834 Free PMC article. - Targeting the cell cycle in breast cancer: towards the next phase.
Thu KL, Soria-Bretones I, Mak TW, Cescon DW. Thu KL, et al. Cell Cycle. 2018;17(15):1871-1885. doi: 10.1080/15384101.2018.1502567. Epub 2018 Sep 11. Cell Cycle. 2018. PMID: 30078354 Free PMC article. Review. - Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC, Ho SC, Tan E, Ng AWT, McPherson JR, Goh GYL, Teh BT, Bard F, Rozen SG. Tang YC, et al. Breast Cancer Res. 2018 Mar 22;20(1):22. doi: 10.1186/s13058-018-0949-3. Breast Cancer Res. 2018. PMID: 29566768 Free PMC article.
References
- Haynes JM, Iannazzo L, Majewski H (2002) Phorbol ester-induced contractility and Ca2+ influx in human cultured prostatic stromal cells. Biochem Pharmacol 64: 385–392. - PubMed
- Shen WH, Balajee AS, Wang J, Wu H, Eng C, et al. (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157–170. - PubMed
- Iorns E, Lord CJ, Turner N, Ashworth A (2007) Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6: 556–568. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous